AT Semicon Decides to Acquire Leaders Technology Investment: "Expanding New Technology Investment and Strengthening Capabilities"

[Asia Economy Reporter Hyunseok Yoo] AT Semicon, a total solution company for semiconductor back-end processes, announced on the 5th that it has signed a stock transfer agreement with Leaders Technology Investment, a new technology investment company.

On the 4th, AT Semicon disclosed that it plans to acquire 20 million shares of Leaders Technology Investment through the stock transfer agreement. Upon completion of the stock acquisition, AT Semicon will become the largest shareholder of Leaders Technology Investment with a 20.67% stake.

A company official stated, "Once the acquisition is completed, we plan to actively utilize the network and solutions related to new technology investments held by Leaders Technology Investment." He added, "In particular, we will secure competitiveness by creating synergy in the newly promoted bio business and establishing a mid- to long-term business strengthening strategy."

Leaders Technology Investment was established in 1986 and has continuously expanded its business, leading to its listing on the KOSDAQ market in 1989. Its main business is investment in new technology ventures, and recently, through stock transfer agreements, it has acquired stakes in Ace Biomed and Genencell, which is developing a COVID-19 treatment. Genencell is a specialized antiviral drug development company that completed Phase 2 clinical trials for a COVID-19 treatment in December last year in collaboration with Kyung Hee University’s Biomedical Research Center and in India.

A company official stated, "The balance payment for the stock transfer is scheduled to be executed on the 20th of next month, and thereafter, an extraordinary general meeting of shareholders will be held to amend the articles of incorporation and appoint registered executives."

This content was produced with the assistance of AI translation services.